Institution
University of Paris
Education•Paris, France•
About: University of Paris is a education organization based out in Paris, France. It is known for research contribution in the topics: Population & Medicine. The organization has 102426 authors who have published 174180 publications receiving 5041753 citations. The organization is also known as: Sorbonne.
Topics: Population, Medicine, Context (language use), Transplantation, Gene
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this article, a framework for the description of both classical and quantum mechanics, within which the continuity of the quantization process is brought out, is presented, and the spectra of some important physical observables are determined by direct phase space methods.
725 citations
••
18 Jul 2001TL;DR: An algorithm to generate Buchi automata from LTL formulae is presented and compared with Spin: the experiments show that the algorithm is much more efficient than Spin.
Abstract: We present an algorithm to generate Buchi automata from LTL formulae. This algorithm generates a very weak alternating co-Buchi automaton and then transforms it into a Buchi automaton, using a generalized Buchi automaton as an intermediate step. Each automaton is simplified on-the-fly in order to save memory and time. As usual we simplify the LTL formula before any treatment. We implemented this algorithm and compared it with Spin: the experiments show that our algorithm is much more efficient than Spin. The criteria of comparison are the size of the resulting automaton, the time of the computation and the memory used. Our implementation is available on the web at the following address: http://verif.liafa.jussieu.fr/ltl2ba
725 citations
••
TL;DR: After 2 years of follow-up, laparoscopic Heller's myotomy, as compared with pneumatic dilation, was not associated with superior rates of therapeutic success.
Abstract: BACKGROUND Many experts consider laparoscopic Heller's myotomy (LHM) to be superior to pneumatic dilation for the treatment of achalasia, and LHM is increasingly considered to be the treatment of choice for this disorder. METHODS We randomly assigned patients with newly diagnosed achalasia to pneumatic dilation or LHM with Dor's fundoplication. Symptoms, including weight loss, dysphagia, retrosternal pain, and regurgitation, were assessed with the use of the Eckardt score (which ranges from 0 to 12, with higher scores indicating more pronounced symptoms). The primary outcome was therapeutic success (a drop in the Eckardt score to ≤3) at the yearly follow-up assessment. The secondary outcomes included the need for retreatment, pressure at the lower esophageal sphincter, esophageal emptying on a timed barium esophagogram, quality of life, and the rate of complications. RESULTS A total of 201 patients were randomly assigned to pneumatic dilation (95 patients) or LHM (106). The mean follow-up time was 43 months (95% confidence interval [CI], 40 to 47). In an intention-to-treat analysis, there was no significant difference between the two groups in the primary outcome; the rate of therapeutic success with pneumatic dilation was 90% after 1 year of follow-up and 86% after 2 years, as compared with a rate with LHM of 93% after 1 year and 90% after 2 years (P=0.46). After 2 years of follow-up, there was no significant between-group difference in the pressure at the lower esophageal sphincter (LHM, 10 mm Hg [95% CI, 8.7 to 12]; pneumatic dilation, 12 mm Hg [95% CI, 9.7 to 14]; P=0.27); esophageal emptying, as assessed by the height of barium-contrast column (LHM, 1.9 cm [95% CI, 0 to 6.8]; pneumatic dilation, 3.7 cm [95% CI, 0 to 8.8]; P=0.21); or quality of life. Similar results were obtained in the per-protocol analysis. Perforation of the esophagus occurred in 4% of the patients during pneumatic dilation, whereas mucosal tears occurred in 12% during LHM. Abnormal exposure to esophageal acid was observed in 15% and 23% of the patients in the pneumatic-dilation and LHM groups, respectively (P=0.28). CONCLUSIONS After 2 years of follow-up, LHM, as compared with pneumatic dilation, was not associated with superior rates of therapeutic success. (European Achalasia Trial Netherlands Trial Register number, NTR37, and Current Controlled Trials number, ISRCTN56304564.).
724 citations
••
Harvard University1, University of Paris2, Columbia University3, University of Colorado Denver4, University College London5, University of Pittsburgh6, Autonomous University of Barcelona7, University of British Columbia8, University of Rochester9, Istituto Superiore di Sanità10, International AIDS Society11, University of California, San Diego12
TL;DR: The International AIDS Society-USA 13-member physician panel with expertise in basic science, clinical research, and patient care involving HIV resistance to antiretroviral drugs was reconvened to provide recommendations for the clinical use of drug resistance testing as discussed by the authors.
Abstract: ObjectiveAssays for drug resistance testing in human immunodeficiency virus type
1 (HIV-1) infection are now available and clinical studies suggest that viral
drug resistance is correlated with poor virologic response to new therapy.
The International AIDS Society–USA sought to update prior recommendations
to provide guidance for clinicians regarding indications for HIV-1 resistance
testing.ParticipantsAn International AIDS Society–USA 13-member physician panel with
expertise in basic science, clinical research, and patient care involving
HIV resistance to antiretroviral drugs was reconvened to provide recommendations
for the clinical use of drug resistance testing.Evidence and Consensus ProcessThe full panel met regularly between January and October 1999. Resistance
and resistance testing data appearing in the last decade through April 2000
and presentations at national and international research conferences were
reviewed. Recommendations and considerations were developed by 100% group
consensus, acknowledging that definitive data to support final recommendations
are not yet available.ConclusionsEmerging data indicate that despite limitations, resistance testing
should be incorporated into patient management in some settings. Resistance
testing is recommended to help guide the choice of new regimens after treatment
failure and for guiding therapy for pregnant women. It should be considered
in treatment-naive patients with established infection, but cannot be firmly
recommended in this setting. Testing also should be considered prior to initiating
therapy in patients with acute HIV infection, although therapy should not
be delayed pending the results. Expert interpretation is recommended given
the complexity of results and assay limitations.
724 citations
••
TL;DR: White adipose tissue was believed to be just an energy-storage organ, but it is now recognized to be an active participant in energy homoeostasis and physiological functions such as immunity and inflammation.
724 citations
Authors
Showing all 102613 results
Name | H-index | Papers | Citations |
---|---|---|---|
Guido Kroemer | 236 | 1404 | 246571 |
David H. Weinberg | 183 | 700 | 171424 |
Paul M. Thompson | 183 | 2271 | 146736 |
Chris Sander | 178 | 713 | 233287 |
Sophie Henrot-Versille | 171 | 957 | 157040 |
Richard H. Friend | 169 | 1182 | 140032 |
George P. Chrousos | 169 | 1612 | 120752 |
Mika Kivimäki | 166 | 1515 | 141468 |
Martin Karplus | 163 | 831 | 138492 |
William J. Sandborn | 162 | 1317 | 108564 |
Darien Wood | 160 | 2174 | 136596 |
Monique M.B. Breteler | 159 | 546 | 93762 |
Paul Emery | 158 | 1314 | 121293 |
Wolfgang Wagner | 156 | 2342 | 123391 |
Joao Seixas | 153 | 1538 | 115070 |